Kolon TissueGene (A950160) Q1 2025 earnings summary

Executive summary

• Focus on cell and gene therapy platform TG-C, targeting osteoarthritis and degenerative disc diseases, with U.S. Phase 3 clinical trials completed for knee OA and Phase 2/1 approvals for hip OA and DDD, respectively.

• Revenue primarily from B2B technology licensing and health/beauty distribution; TG-C not yet commercialized.

• Significant R&D investment, with pipeline expansion into additional musculoskeletal and autoimmune indications.

Financial highlights

• Q1 2025 revenue: $887K (USD), down from $3.7M in 2024 and $2.8M in 2023.

• Operating loss Q1 2025: $(3.7)M; net loss: $(4.0)M; basic/diluted EPS: $(0.25).

• Cash and equivalents at Q1 2025: $36.3M, up from $546K at 2024 year-end, driven by equity and convertible bond issuances.

• R&D expenses Q1 2025: $2.3M; capitalized development costs: $22.9M.

• Total assets: $210.8M; equity: $125.3M; liabilities: $85.5M.

Outlook and guidance

• Plans to file for FDA BLA after 2-year follow-up of Phase 3 knee OA trial; commercialization targeted post-approval.

• Pipeline expansion into hip OA, DDD, rheumatoid arthritis, and animal health; additional clinical trials planned.

• Continued focus on licensing and strategic partnerships for global commercialization.